Clinical Trial: ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

U.S., Jan. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07318389) titled 'ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer' on Dec. 30, 2025.

Brief Summary: To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.

Study Start Date: June 10, 2026

Study Type: INTERVENTIONAL

Condition: Dynamic Tumor Resistance Metastatic Colorectal Cancer

Intervention: OTHER: SOC (Standard of care)

Blood draws, biopsies, samples and MRI.

DRUG: Bevacizumab

Given by IV

DRUG: Cetuximab

Given by Iv

DRUG: Panitumumab

Given by Iv

DRUG: FOLFIRI

Give...